Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study

MLA

Daniel H. Leung, et al. “Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.” Hepatology, vol. 74, July 2021, pp. 19–27. EBSCOhost, https://doi.org/10.1002/hep.31841.

APA

Daniel H. Leung, Andrew Topp, Cornelia Feiterna-Sperling, Antonio Del Valle-Segarra, John Marcinak, Regino P. Gonzalez-Peralta, Steven Lobritto, Rakesh Tripathi, Vishakha Sabharwal, Simon C. Ling, Susan Gilmour, Jessica Wen, Loreto Hierro, Hoi Kei Lon, Yuri Lobzin, Maureen M. Jonas, Deirdre Kelly, Etienne Sokal, Michael R. Narkewicz, … Susan Rhee. (2021). Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology, 74, 19–27. https://doi.org/10.1002/hep.31841

Chicago

Daniel H. Leung, Andrew Topp, Cornelia Feiterna-Sperling, Antonio Del Valle-Segarra, John Marcinak, Regino P. Gonzalez-Peralta, Steven Lobritto, et al. 2021. “Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.” Hepatology 74 (July): 19–27. doi:10.1002/hep.31841.